We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis
Effectiveness and Safety of Twincretin Survodutide, a Drug Acting on Two Hormone Receptors, for Treating Obesity and Diabetes
AI simplified
Abstract
Survodutide resulted in a 9.14 kg and 10.23 kg body weight reduction at doses of 2.4 mg and 3.6 mg, respectively.
- A significant percent reduction in body weight was observed with survodutide compared to placebo, with reductions of -7.79% for 2.4 mg and -9.08% for 3.6 mg.
- Survodutide at 2.4 mg was associated with a significant reduction in levels, showing a mean difference of -0.88%.
- Treatment-emergent adverse events were significantly higher with survodutide at both 2.4 mg and 3.6 mg doses compared to placebo.
- Gastrointestinal adverse events were the most common and were dependent on the dose of survodutide.
- Treatment discontinuation due to adverse events was significantly higher with survodutide and also dose dependent.
AI simplified
Key numbers
-7.79%
Percent Reduction in Body Weight (2.4 mg/week)
Percent change in body weight from baseline.
-10.23 kg
Absolute Weight Reduction (3.6 mg/week)
Mean difference in weight from baseline.
-0.88%
Reduction (2.4 mg/week)
Mean difference in from baseline.